GlaxoSmithKline agrees to pay over $1 million to Idaho for deceptive promotion of drug
Idaho will receive $1.33 million from a consent judgment reached between GlaxoSmithKline LLC and 37 other state Attorneys General.
According to Attorney General Lawrence Wasden, the company has not admitted to any wrongdoing, but agreed to pay $90 million to resolve allegations that it unlawfully promoted its diabetes drug, Avandia.
"The states allege that GlaxoSmithKline made claims that Avandia had cardiovascular benefits, which it did not," said Wasden. "The drug may actually increase cardiovascular risks."
Idaho’s portion of the settlement will be deposited in the Consumer Protection Account, which is subject to legislative appropriation. This is the third settlement the Attorney General’s Consumer Protection Division has reached with GlaxoSmithKline.